JPRN-jRCT1001220001已完成Unknown
Administration study of long-acting growth hormone preparations in healthy adults
Yonemura Takuma0 个研究点目标入组 12 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 35age old（—）
- 性别
- All
入选标准
- •1) Men BMI18.5 or more but less than 25.0 at the time of prior examination.
- •2) Women: BMI 17.6 or more and less than 26.4 at the time of prior examination.
- •Person who is judged by Principal investigator or Sub-investigator that there is no problem with participation in the test.
排除标准
- •1) Subjects who have had allergic symptoms due to drugs
- •2) Subjects who are being treated for some disease or who may receive treatment during the study period
- •3) Those who are suspected of suffering from or have a history of the following diseases
- •Test drug-1
- •benign intracranial hypertension, hypoadrenocorticism, diabetes, diabetic complications, brain tumor,
- •Heart disease, renal dysfunction, liver dysfunction
- •Test drug-2
- •malignant tumor, hypothyroidism, hypoadrenocorticism, diabetes, brain tumor, heart disease,
- •renal dysfunction
- •4) Subjects who are alcoholic or drug dependent, or have a history of depression.
- •5) Subjects who used ethical drugs or over-the-counter drugs within 2 weeks of the scheduled administration of the study drug
- •6)Subjects who took supplements, foods containing St. John's wort, grapefruit, or processed products thereof within 1 week of scheduled administration of the study drug
- •7) Subjects who received another investigational drug or investigational drug within 16 weeks of the scheduled administration date of the investigational drug, or an investigational drug or investigational drug containing an approved ingredient within 12 weeks
- •8) Subjects who received 200 mL or more of blood within 30 days of the scheduled administration of the study drug, 400 mL or more of blood within 90 days, and those who received component blood donation within 14 days of the scheduled administration of the study drug.
- •9) Subjects weighing less than 40kg and 90kg or more at the time of pre-examination
- •10) Those who are suspected of having a new coronavirus infection
- •11) Lactating women, pregnant women, and those who may become pregnant during the study period
- •12) Subjects who are judged inappropriate for participation in this study by the principal investigator or subinvestigator
研究者
相似试验
已完成
不适用
Short term recombinant human Growth Hormone administration increases strength and power, but does it improve sporting performance in anabolic-androgenic steroid users?Anabolic-Androgenic Steroid (AAS) usersSteroid usersISRCTN13681882niversity of Glamorgan48
进行中（未招募）
2 期
Evaluation of Growth Hormone Treatment in adolescence: Effect on body composition, bones, glucose and lipids in patients who were treated with this hormoneOsteoporosisRBR-29sg4xgniversidade de São Paulo
尚未招募
3 期
Investigating the results of adding growth hormone to the ovulation stimulation regimen in microinjection and In Vitro Fertilization in patients with low ovarian reserveIRCT20130603013566N13Vice chancellor for Research,Tabriz University Of Medical Sciences96
已完成
不适用
Efficacy and safety of growth hormone treatment in short children born small for gestational age; effects of growth hormone levels on growth, insulin sensitivity and body compositioSmall for gestational age (SGA), children with persistent short staturePregnancy and ChildbirthSlow foetal growthISRCTN65230311Erasmus Medical Center (The Netherlands)157
进行中（未招募）
不适用
A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults - Growth Hormone and Quality of Life (GroH-QoL)EUCTR2004-004835-72-GBniversity of Birmingham200